Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arrhythmic risk stratification in psoriatic arthritis: a retrospective, electrogram-based comparative analysis.

RMD open·2026
Same author

QT Interval Evaluation in Right Ventricular Pacing: Validation of a Novel Formula.

Pacing and clinical electrophysiology : PACE·2026
Same author

Sauna Therapy in HFpEF: More than Just Heat?

European journal of heart failure·2026
Same author

Intraindividual Lp(a)-Variability in a Real-World Setting.

JACC. Advances·2026
Same author

Rhythm control in persistent atrial fibrillation improves endothelial function without uniform anti-inflammatory effects: A 9-month prospective cohort study.

International journal of cardiology. Heart & vasculature·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026

Related Experiment Video

Updated: May 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Renal denervation and heart failure.

Michael Böhm1, Sebastian Ewen, Ingrid Kindermann

  • 1Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.

European Journal of Heart Failure
|March 20, 2014
PubMed
Summary

Renal denervation lowers blood pressure and heart rate in resistant hypertension and heart failure. This sympathetic nervous system modulation may also offer therapeutic benefits for arrhythmias in chronic heart failure patients.

Keywords:
Heart failureHypertensionRenal sympathetic denervationSympathetic nervous system

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

847
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.2K

Related Experiment Videos

Last Updated: May 2, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

847
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.2K

Area of Science:

  • Cardiology
  • Nephrology
  • Hypertension Management

Background:

  • Sympathetic nervous system overactivation is linked to cardiovascular disease progression, particularly in resistant hypertension and heart failure.
  • Renal norepinephrine release is a key marker of sympathetic activity associated with morbidity and mortality in heart failure.
  • Renal denervation aims to reduce sympathetic nerve activity impacting the kidneys.

Purpose of the Study:

  • To evaluate the clinical efficacy of renal denervation in managing resistant hypertension and heart failure.
  • To explore the potential antiarrhythmic effects of renal denervation in chronic heart failure.
  • To assess the broader impact of renal denervation on cardiovascular and renal parameters.

Main Methods:

  • Studies involve assessing the effects of renal denervation on systolic blood pressure and heart rate.
  • Evaluation of secondary outcomes including myocardial hypertrophy, glucose tolerance, and microalbuminuria.
  • Planned proof-of-concept studies to investigate clinical applications.

Main Results:

  • Initial studies indicate renal denervation effectively reduces both blood pressure and heart rate.
  • Observed benefits include reduced myocardial hypertrophy, improved glucose tolerance, and ameliorated microalbuminuria.
  • Experimental data suggest a potential antiarrhythmic role for renal denervation.

Conclusions:

  • Renal denervation is a promising therapeutic strategy for resistant hypertension and heart failure.
  • The procedure may offer significant benefits beyond blood pressure control, including antiarrhythmic effects.
  • Further clinical studies are warranted to establish renal denervation's role in changing clinical practice for cardiovascular conditions.